90794-9
Vedolizumab and Vedolizumab Ab panel [Mass/volume] - Serum or Plasma
Active
86898-4 Vedolizumab [Mass/volume] in Serum or Plasma by Immunoassay
Term Description
This term was created for, but not limited in use to, the submitter's Theradiag Lisa-Tracker Vedolizumab and anti-Vedolizumab test kits.
Part Descriptions
LP250843-2 Vedolizumab
Vedolizumab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD) including the subtypes Ulcerative colitis and Crohn's disease. IBD involves inflammation of the intestinal mucosa by leukocytes that cause a disruption in its barrier function. The leukocytes involved are T-cells that express α4β7 integrins which are the target for the drug vedolizumab. Vedolizumab prevents α4β7 integrin from binding with the endothelial surface and T-cells from penetrating the intestinal mucosa. Vedolizumab has proven to be a safe and effective treatment for IBD based in clinical research. Clinical studies have shown that vedolizumab helps achieve corticosteroid-free clinical remission. PMID: 27003961
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- Vedolizumab
- Property
- MCnc
- Time
- Pt
- System
- Ser/Plas
- Scale
- Qn
- Method
- IA
Basic Attributes
- Class
- DRUG/TOX
- Type
- Laboratory
- First Released
- Version 2.63
- Last Updated
- Version 2.73 (MIN)
- Order vs. Observation
- Both
- Common Test Rank Get Info
- 10450
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 90794-9 | Vedolizumab and Vedolizumab Ab panel [Mass/volume] - Serum or Plasma |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| el-GR | Greek (Greece) | Βεδολιζουμάμπη: Synonyms: MCnc Βεδολιζουμάμπη |
| es-ES | Spanish (Spain) | Vedolizumab: Synonyms: Cuantitativo |
| es-MX | Spanish (Mexico) | Vedolizumab: |
| fr-FR | French (France) | Védolizumab: |
| it-IT | Italian (Italy) | Vedolizumab: Synonyms: Concentrazione di Massa Immunoassay Livelli farmacologici e tossicologia Plasma Punto nel tempo (episodio) Siero Siero o Plasma |
| zh-CN | Chinese (China) | 维多珠单抗: Synonyms: 免疫测定; |
Example Units
| Unit | Source |
|---|---|
| ug/mL | Example UCUM Units |
86899-2 Vedolizumab Ab [Mass/volume] in Serum or Plasma by Immunoassay
Term Description
This term was created for, but not limited in use to, the submitter's Theradiag Lisa-Tracker Vedolizumab and anti-Vedolizumab test kits.
Part Descriptions
LP250843-2 Vedolizumab
Vedolizumab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD) including the subtypes Ulcerative colitis and Crohn's disease. IBD involves inflammation of the intestinal mucosa by leukocytes that cause a disruption in its barrier function. The leukocytes involved are T-cells that express α4β7 integrins which are the target for the drug vedolizumab. Vedolizumab prevents α4β7 integrin from binding with the endothelial surface and T-cells from penetrating the intestinal mucosa. Vedolizumab has proven to be a safe and effective treatment for IBD based in clinical research. Clinical studies have shown that vedolizumab helps achieve corticosteroid-free clinical remission. PMID: 27003961
Source: Regenstrief LOINC
LP250846-5 Vedolizumab Ab
In clinical trials, antibodies to vedolizumab (ATV) were present in about 4% of patients at any given time and were persistent in only 1% or less of patients receiving vedolizumab. [https://www.healthcare.uiowa.edu/path_handbook/handbook/test3424.html] In those patients with anti-vedolizumab antibodies, vedolizumab clearance was increased by about 12%, and for those with persistent antibodies, the trough concentration of vedolizumab was below detectable limits. Anti-drug antibodies can be one cause of treatment failure for vedolizumab as well as other monoclonal antibody therapeutics. PMID: 25996351
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- Vedolizumab Ab
- Property
- MCnc
- Time
- Pt
- System
- Ser/Plas
- Scale
- Qn
- Method
- IA
Basic Attributes
- Class
- DRUG/TOX
- Type
- Laboratory
- First Released
- Version 2.63
- Last Updated
- Version 2.73 (MIN)
- Order vs. Observation
- Both
- Common Test Rank Get Info
- 6276
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 90794-9 | Vedolizumab and Vedolizumab Ab panel [Mass/volume] - Serum or Plasma |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| el-GR | Greek (Greece) | Βεδολιζουμάμπη Αντίσωμα: Synonyms: MCnc Βεδολιζουμάμπη |
| es-ES | Spanish (Spain) | Vedolizumab Anticuerpos: Synonyms: Cuantitativo |
| es-MX | Spanish (Mexico) | Vedolizumab Ab: |
| fr-FR | French (France) | Védolizumab anticorps: |
| it-IT | Italian (Italy) | Vedolizumab Ab: Synonyms: anticorpo Concentrazione di Massa Immunoassay Livelli farmacologici e tossicologia Plasma Punto nel tempo (episodio) Siero Siero o Plasma |
| zh-CN | Chinese (China) | 维多珠单抗 抗体: Synonyms: Ab; |
Example Units
| Unit | Source |
|---|---|
| ng/mL | Example UCUM Units |
90805-3 Vedolizumab [Mass/volume] in Serum or Plasma by LC/MS/MS --trough
Term Description
Vedolizumab trough levels are measured immediately before the next scheduled dose.
Part Descriptions
LP20176-1 trough
In medicine, a trough level is the lowest level that a medicine is present in the body. In a medicine that is administered periodically, the trough level should be measured just before the administration of the next dose in order to avoid overdosing. It should be contrasted with a "peak level", which is the highest level of the medicine in the body, and the "average level", which is the mean level over time. It helps in therapeutic drug monitoring. It is widely used in clinical trials for newer medicines for its therapeutic effectiveness and safety.
Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
Source: Wikipedia
, Trough levels for therapeutic drug monitoring
LP250843-2 Vedolizumab
Vedolizumab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD) including the subtypes Ulcerative colitis and Crohn's disease. IBD involves inflammation of the intestinal mucosa by leukocytes that cause a disruption in its barrier function. The leukocytes involved are T-cells that express α4β7 integrins which are the target for the drug vedolizumab. Vedolizumab prevents α4β7 integrin from binding with the endothelial surface and T-cells from penetrating the intestinal mucosa. Vedolizumab has proven to be a safe and effective treatment for IBD based in clinical research. Clinical studies have shown that vedolizumab helps achieve corticosteroid-free clinical remission. PMID: 27003961
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- Vedolizumab^trough
- Property
- MCnc
- Time
- Pt
- System
- Ser/Plas
- Scale
- Qn
- Method
- LC/MS/MS
Basic Attributes
- Class
- DRUG/TOX
- Type
- Laboratory
- First Released
- Version 2.65
- Last Updated
- Version 2.65 (ADD)
- Order vs. Observation
- Both
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 90794-9 | Vedolizumab and Vedolizumab Ab panel [Mass/volume] - Serum or Plasma |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| el-GR | Greek (Greece) | Βεδολιζουμάμπη^ελάχιστα επίπεδα: Synonyms: MCnc Βεδολιζουμάμπη |
| es-MX | Spanish (Mexico) | Vedolizumab ^ a través: |
| es-ES | Spanish (Spain) | Vedolizumab^Valle monitorización terapéutica de fármacos: Synonyms: Cuantitativo |
| fr-FR | French (France) | Védolizumab taux résiduel: |
| it-IT | Italian (Italy) | Vedolizumab^valore minimo: Synonyms: Concentrazione di Massa Livelli farmacologici e tossicologia Plasma Punto nel tempo (episodio) Siero Siero o Plasma valore minimo TDM |
| zh-CN | Chinese (China) | 维多珠单抗^波谷: Synonyms: Tandem Mass Spectrometry; |
Example Units
| Unit | Source |
|---|---|
| ug/mL | Example UCUM Units |